JP5027209B2 - クローン病患者の末梢血白血球におけるＴ細胞受容体介在性腫瘍壊死因子スーパーファミリー及びケモカインのｍＲＮＡ発現の増強 - Google Patents
クローン病患者の末梢血白血球におけるＴ細胞受容体介在性腫瘍壊死因子スーパーファミリー及びケモカインのｍＲＮＡ発現の増強 Download PDFInfo
- Publication number
- JP5027209B2 JP5027209B2 JP2009504317A JP2009504317A JP5027209B2 JP 5027209 B2 JP5027209 B2 JP 5027209B2 JP 2009504317 A JP2009504317 A JP 2009504317A JP 2009504317 A JP2009504317 A JP 2009504317A JP 5027209 B2 JP5027209 B2 JP 5027209B2
- Authority
- JP
- Japan
- Prior art keywords
- sample
- mrna
- tnfsf
- leukocytes
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 102
- 208000011231 Crohn disease Diseases 0.000 title claims abstract description 75
- 210000000265 leukocyte Anatomy 0.000 title claims description 90
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title claims description 36
- 108010012236 Chemokines Proteins 0.000 title claims description 33
- 102000019034 Chemokines Human genes 0.000 title claims description 32
- 102000003390 tumor necrosis factor Human genes 0.000 title claims 5
- 108091008874 T cell receptors Proteins 0.000 title description 22
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title description 21
- 230000014509 gene expression Effects 0.000 title description 14
- 210000005259 peripheral blood Anatomy 0.000 title description 10
- 239000011886 peripheral blood Substances 0.000 title description 10
- 230000001404 mediated effect Effects 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 53
- 238000011282 treatment Methods 0.000 claims abstract description 38
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 230000008685 targeting Effects 0.000 claims abstract description 7
- 210000004369 blood Anatomy 0.000 claims description 60
- 239000008280 blood Substances 0.000 claims description 60
- 230000000638 stimulation Effects 0.000 claims description 57
- 238000000338 in vitro Methods 0.000 claims description 44
- 230000004936 stimulating effect Effects 0.000 claims description 37
- 210000004027 cell Anatomy 0.000 claims description 32
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 31
- 230000002776 aggregation Effects 0.000 claims description 30
- 238000004220 aggregation Methods 0.000 claims description 30
- 108010062580 Concanavalin A Proteins 0.000 claims description 21
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000002158 endotoxin Substances 0.000 claims description 21
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 21
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 claims description 21
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 20
- 108010047620 Phytohemagglutinins Proteins 0.000 claims description 20
- 230000001885 phytohemagglutinin Effects 0.000 claims description 20
- 102000005962 receptors Human genes 0.000 claims description 18
- 108020003175 receptors Proteins 0.000 claims description 18
- 239000003446 ligand Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 14
- 229920000855 Fucoidan Polymers 0.000 claims description 11
- 108060003951 Immunoglobulin Proteins 0.000 claims description 10
- 102000018358 immunoglobulin Human genes 0.000 claims description 10
- 229960000598 infliximab Drugs 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 8
- 230000035897 transcription Effects 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 5
- 108010036949 Cyclosporine Proteins 0.000 claims description 5
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 5
- 229960001265 ciclosporin Drugs 0.000 claims description 5
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 5
- 229960001967 tacrolimus Drugs 0.000 claims description 5
- 229930105110 Cyclosporin A Natural products 0.000 claims description 4
- 239000002085 irritant Substances 0.000 claims description 2
- 231100000021 irritant Toxicity 0.000 claims description 2
- -1 jacarin Polymers 0.000 claims 4
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 abstract description 12
- 150000001875 compounds Chemical class 0.000 abstract description 7
- 238000012544 monitoring process Methods 0.000 abstract description 6
- 238000012216 screening Methods 0.000 abstract description 6
- 102000004127 Cytokines Human genes 0.000 abstract description 3
- 108090000695 Cytokines Proteins 0.000 abstract description 3
- 239000000523 sample Substances 0.000 description 59
- 239000007787 solid Substances 0.000 description 16
- 108010087819 Fc receptors Proteins 0.000 description 14
- 102000009109 Fc receptors Human genes 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 208000023275 Autoimmune disease Diseases 0.000 description 9
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 8
- 102100039065 Interleukin-1 beta Human genes 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 108090001007 Interleukin-8 Proteins 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000002784 cytotoxicity assay Methods 0.000 description 6
- 231100000263 cytotoxicity test Toxicity 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000021 stimulant Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 108010084553 jacalin Proteins 0.000 description 5
- 229940116176 remicade Drugs 0.000 description 5
- 230000004043 responsiveness Effects 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710082514 C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 102000000018 Chemokine CCL2 Human genes 0.000 description 1
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79035406P | 2006-04-07 | 2006-04-07 | |
| US60/790,354 | 2006-04-07 | ||
| PCT/US2007/008597 WO2007117611A2 (en) | 2006-04-07 | 2007-04-05 | Enhanced t cell receptor-mediated tumor necrosis factor superfamily and chemokine mrna expression in peripheral blood leukocytes in patients with crohn's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009535016A JP2009535016A (ja) | 2009-10-01 |
| JP2009535016A5 JP2009535016A5 (enExample) | 2010-01-14 |
| JP5027209B2 true JP5027209B2 (ja) | 2012-09-19 |
Family
ID=38581650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009504317A Expired - Fee Related JP5027209B2 (ja) | 2006-04-07 | 2007-04-05 | クローン病患者の末梢血白血球におけるＴ細胞受容体介在性腫瘍壊死因子スーパーファミリー及びケモカインのｍＲＮＡ発現の増強 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7838239B2 (enExample) |
| EP (1) | EP2005175B1 (enExample) |
| JP (1) | JP5027209B2 (enExample) |
| CN (1) | CN101410714A (enExample) |
| AT (1) | ATE518011T1 (enExample) |
| WO (1) | WO2007117611A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1776471B9 (en) * | 2004-05-25 | 2013-12-18 | Hitachi Chemical Company, Ltd. | Method of measuring cancer susceptibility |
| JP4772055B2 (ja) * | 2004-10-20 | 2011-09-14 | 日立化成工業株式会社 | ｍＲＮＡの定量により薬剤の投与を選定する方法 |
| US12110555B2 (en) | 2004-12-08 | 2024-10-08 | Cedars-Sinai Medical Center | Diagnosis and treatment of inflammatory bowel disease |
| US11268149B2 (en) | 2004-12-08 | 2022-03-08 | Cedars-Sinai Medical Center | Diagnosis and treatment of inflammatory bowel disease |
| US10544459B2 (en) | 2004-12-08 | 2020-01-28 | Cedars-Sinai Medical Center | Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease |
| JP4945554B2 (ja) * | 2005-04-28 | 2012-06-06 | ヒタチ ケミカル リサーチ センター インコーポレイテッド | 食物サプリメントに対する個体変動評価のモデルとしての全血におけるｅｘｖｉｖｏ遺伝子発現 |
| WO2009070442A2 (en) | 2007-11-14 | 2009-06-04 | Hitachi Chemical Co. Ltd. | Fc receptor-mediated tumor necrosis factor superfamily mrna expression in peripheral blood leukocytes |
| DE102006051628A1 (de) | 2006-11-02 | 2008-05-08 | Daimler Ag | Abgasturbolader für eine Brennkraftmaschine |
| US20100015156A1 (en) * | 2007-03-06 | 2010-01-21 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease in children |
| US8486640B2 (en) | 2007-03-21 | 2013-07-16 | Cedars-Sinai Medical Center | Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease |
| EP2056110A1 (en) | 2007-10-31 | 2009-05-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment |
| US20110229471A1 (en) * | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| US9580752B2 (en) | 2008-12-24 | 2017-02-28 | Cedars-Sinai Medical Center | Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy |
| EP2992792B1 (en) * | 2010-11-11 | 2017-03-15 | Nestec S.A. | Beverage production machine and rinsing and/or descaling insert |
| US9902996B2 (en) | 2011-02-11 | 2018-02-27 | Cedars-Sinai Medical Center | Methods of predicting the need for surgery in crohn's disease |
| EP2734233B1 (en) * | 2011-07-18 | 2017-11-01 | Hitachi Chemical Co., Ltd. | Methods of predicting host responsiveness to cancer immunotherapies by ex vivo induction of leukocyte-function-associated mrnas |
| KR20240122922A (ko) | 2013-03-27 | 2024-08-13 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전 |
| EP4105236A1 (en) | 2013-07-19 | 2022-12-21 | Cedars-Sinai Medical Center | Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease |
| CN103865998B (zh) * | 2013-12-16 | 2016-04-20 | 周菊华 | 一种肿瘤免疫治疗效果的基因检测方法 |
| US20150257586A1 (en) * | 2014-03-11 | 2015-09-17 | Starbucks Corporation Dba Starbucks Coffee Company | Single-serve beverage production machine |
| US11028443B2 (en) | 2015-08-31 | 2021-06-08 | Showa Denko Materials Co., Ltd. | Molecular methods for assessing urothelial disease |
| CN109462996A (zh) | 2016-03-17 | 2019-03-12 | 西达-赛奈医疗中心 | 通过rnaset2诊断炎性肠病的方法 |
| WO2020232125A1 (en) | 2019-05-14 | 2020-11-19 | Prometheus Biosciences, Inc. | Tl1a patient selection methods, systems, and devices |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4925572A (en) | 1987-10-20 | 1990-05-15 | Pall Corporation | Device and method for depletion of the leukocyte content of blood and blood components |
| US4880548A (en) | 1988-02-17 | 1989-11-14 | Pall Corporation | Device and method for separating leucocytes from platelet concentrate |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US5491063A (en) | 1994-09-01 | 1996-02-13 | Hoffmann-La Roche Inc. | Methods for in-solution quenching of fluorescently labeled oligonucleotide probes |
| PT938320E (pt) | 1996-03-26 | 2010-09-22 | Michael S Kopreski | Método que permite a utilização de arn extracelular extraído de plasma ou de soro para detectar, monitorizar ou avaliar o cancro |
| US5683698A (en) | 1996-08-02 | 1997-11-04 | New England Deaconess Hospital | Formulation for alleviating symptoms associated with arthritis |
| US7514232B2 (en) | 1996-12-06 | 2009-04-07 | Becton, Dickinson And Company | Method for detecting T cell response to specific antigens in whole blood |
| US6183951B1 (en) * | 1997-04-11 | 2001-02-06 | Prometheus Laboratories, Inc. | Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy |
| US20020006613A1 (en) | 1998-01-20 | 2002-01-17 | Shyjan Andrew W. | Methods and compositions for the identification and assessment of cancer therapies |
| WO2000076492A1 (en) | 1999-06-15 | 2000-12-21 | Nutri-Logics, Inc. | Nutrient formulations for disease reduction, and related treatment and component screening methods |
| US6692916B2 (en) | 1999-06-28 | 2004-02-17 | Source Precision Medicine, Inc. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
| US20020048566A1 (en) | 2000-09-14 | 2002-04-25 | El-Deiry Wafik S. | Modulation of cellular apoptosis and methods for treating cancer |
| US7374881B2 (en) * | 2000-10-31 | 2008-05-20 | Hitachi Chemical Research Center, Inc. | Method for collecting and using nuclear mRNA |
| US20020182274A1 (en) | 2001-03-21 | 2002-12-05 | Kung-Ming Lu | Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| JP5236856B2 (ja) * | 2001-11-09 | 2013-07-17 | ライフ テクノロジーズ コーポレーション | 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定 |
| CA2467629A1 (en) | 2001-11-20 | 2003-05-30 | Oncomedx, Inc. | Methods for evaluating drug-resistance gene expression in the cancer patient |
| US7871619B2 (en) | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| FI20020078A7 (fi) | 2002-01-15 | 2003-07-16 | Danisco | Immuunijärjestelmän stimulointi polydextroosilla |
| US6878518B2 (en) | 2002-01-22 | 2005-04-12 | The Trustees Of The University Of Pennsylvania | Methods for determining steroid responsiveness |
| US7745180B2 (en) | 2002-04-24 | 2010-06-29 | Hitachi Chemical Co., Ltd. | Device and method for high-throughput quantification of mRNA from whole blood |
| EP1507548B1 (en) | 2002-05-27 | 2014-10-01 | CanImGuide Therapeutics AB | Method for determining immune system affecting compounds |
| AU2002953533A0 (en) | 2002-12-24 | 2003-01-16 | Arthron Limited | Fc receptor modulating compounds and compositions |
| EP1776471B9 (en) | 2004-05-25 | 2013-12-18 | Hitachi Chemical Company, Ltd. | Method of measuring cancer susceptibility |
| US8110347B2 (en) | 2005-04-15 | 2012-02-07 | Canimguide Therapeutics Ab | Diagnostic method for detecting cancer by measuring amount of cytokine like IL-6 |
| JP4945554B2 (ja) | 2005-04-28 | 2012-06-06 | ヒタチ ケミカル リサーチ センター インコーポレイテッド | 食物サプリメントに対する個体変動評価のモデルとしての全血におけるｅｘｖｉｖｏ遺伝子発現 |
| US7935482B2 (en) | 2005-09-27 | 2011-05-03 | Source Precision Medicine, Inc. | Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis |
| US20100190162A1 (en) | 2007-02-26 | 2010-07-29 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
-
2007
- 2007-04-05 JP JP2009504317A patent/JP5027209B2/ja not_active Expired - Fee Related
- 2007-04-05 US US12/296,425 patent/US7838239B2/en not_active Expired - Fee Related
- 2007-04-05 WO PCT/US2007/008597 patent/WO2007117611A2/en not_active Ceased
- 2007-04-05 EP EP07755012A patent/EP2005175B1/en not_active Not-in-force
- 2007-04-05 CN CNA2007800115431A patent/CN101410714A/zh active Pending
- 2007-04-05 AT AT07755012T patent/ATE518011T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101410714A (zh) | 2009-04-15 |
| EP2005175A2 (en) | 2008-12-24 |
| WO2007117611A3 (en) | 2008-08-07 |
| EP2005175A4 (en) | 2009-06-03 |
| US7838239B2 (en) | 2010-11-23 |
| US20090253133A1 (en) | 2009-10-08 |
| ATE518011T1 (de) | 2011-08-15 |
| EP2005175B1 (en) | 2011-07-27 |
| JP2009535016A (ja) | 2009-10-01 |
| WO2007117611A2 (en) | 2007-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5027209B2 (ja) | クローン病患者の末梢血白血球におけるＴ細胞受容体介在性腫瘍壊死因子スーパーファミリー及びケモカインのｍＲＮＡ発現の増強 | |
| JP5727484B2 (ja) | Ｉ型インターフェロン診断法 | |
| US8268566B2 (en) | Enhanced FC receptor-mediated tumor necrosis factor superfamily MRNA expression in peripheral blood leukocytes in patients with rheumatoid arthritis | |
| JP4800384B2 (ja) | 腫瘍細胞及び刺激された白血球におけるｍＲＮＡの発現プロファイルに基づく腫瘍性疾患に対する免疫応答を予測する方法 | |
| JP5706913B2 (ja) | 攻撃的及び防御的免疫マーカーのｅｘｖｉｖｏ誘導により宿主免疫機能を特徴付けるための方法 | |
| Nieto et al. | Effect of lipopolysaccharide infusion on gene expression of inflammatory cytokines in normal horses in vivo | |
| JP5837691B2 (ja) | 白血球機能関連ｍＲＮＡの生体外での誘導によって癌免疫療法に対するホストの応答性を予測する方法 | |
| CN109996895A (zh) | 体外诊断精神障碍的方法和生物标志物 | |
| JP2009536021A (ja) | 関節リウマチの患者の末梢血白血球におけるＦＣ受容体媒介性腫瘍壊死因子スーパーファミリ及びケモカインのｍＲＮＡ発現の増大 | |
| Mrazek et al. | Expression of the chemokine PARC mRNA in bronchoalveolar cells of patients with sarcoidosis | |
| US9150920B2 (en) | Methods of characterizing host responsiveness to interferon by ex vivo induction of interferon-responsive markers | |
| JP2007522800A (ja) | 内皮細胞の発現プロファイルを用いた組織炎症応答の評価方法 | |
| AU2011268223B2 (en) | Method for predicting a therapy response in subjects with multiple sclerosis | |
| US20070117105A1 (en) | Interferon assay | |
| ES2971091T3 (es) | Un método para supervisar las respuestas farmacodinámicas mediadas por la administración de glucocorticoides in vivo | |
| Mitsuhashi | Ex vivo simulation of leukocyte function: stimulation of specific subset of leukocytes in whole blood followed by the measurement of function-associated mRNAs | |
| Giorgio et al. | Venetoclax and Tumor Lysis Syndrome (TLS): Data Mining of the FDA Adverse Event Reporting System (FAERS) Database | |
| CN120035681A (zh) | 对膀胱癌对象的结果的预测 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110712 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111012 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120522 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120621 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150629 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5027209 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150629 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees | ||
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |